## A: Agilent Technologies, Inc. - XLV: Healthcare

### Executive Summary

STRENGTH thesis confirmed: MRS_10 at 5.5% in upper entry zone (3.0-6.0%), top quartile (86th pct) cross-sectional ranking. Short-term MRS_5 (4.3%) confirms momentum alignment. Strong momentum (+6.1% 5-day acceleration). Outperforming sector by 3.8%.

- **Horizon:** 5-20 days (swing)
- **Risk Profile:** Moderate - momentum continuation
- **Stop Type:** Fixed 2xATR ($141.48)
- **If Wrong:** Exit if MRS_10 drops below entry zone or breaks stop
- **Invalidation:** MRS_10 exits entry zone or MRS_5 turns negative

### News

- **Articles:** 8
- **Sentiment:** Bullish (Bullish: 2, Bearish: 0)

**1. Who Owns Agilent Technologies? Top Shareholders and Recent Insider Trades**
- Source: TIKR.com | 20260104T130726 | Neutral | Relevance: 100%
- This article details the top institutional shareholders of Agilent Technologies (NYSE: A), highlighting major passive and active investors. It also reviews recent insider trades, noting that executives and directors have made small sales, which appear to be for personal portfolio management rather than signaling a negative outlook. The overall picture suggests Agilent remains a stable, institutionally supported business.

**2. The Truth About Agilent Technologies Inc: Quiet Lab Stock That Might Be Your Next Power Play**
- Source: AD HOC NEWS | 20260105T232946 | Bullish | Relevance: 100%
- Agilent Technologies Inc (A) is presented as a quiet yet powerful player in the lab technology sector, supporting pharma, biotech, and semiconductor industries. The article suggests that while it lacks the viral "hype" of AI or meme stocks, its "picks-and-shovels" business model, steady growth, and integral role in scientific research make it a compelling long-term investment. It is compared to competitors like Thermo Fisher Scientific, highlighting Agilent's focus on precision instruments and analytics.

**3. Agilent Technologies (NYSE:A) Upgraded at Evercore ISI**
- Source: MarketBeat | 20260105T135750 | Bullish | Relevance: 100%
- Agilent Technologies (NYSE:A) has been upgraded by Evercore ISI from "in-line" to "outperform" with a $160 price target, suggesting a 16% upside. The company recently surpassed its earnings expectations, reporting $1.59 EPS against $1.58 expected and $1.86B in revenue, and has issued optimistic guidance for Q1 and FY 2026. Despite some insider selling, institutional investors like Arrowstreet Capital have significantly increased their stakes in the medical research company.

**4. Penobscot Investment Management Company Inc. Sells 8,029 Shares of Agilent Technologies, Inc. $A**
- Source: MarketBeat | 20260104T122049 | Somewhat-Bullish | Relevance: 95%
- Penobscot Investment Management Company Inc. reduced its stake in Agilent Technologies (NYSE:A) by 38.5%, selling 8,029 shares and holding 12,846 shares valued at approximately $1.65 million. This divestment comes as Agilent Technologies reported strong quarterly earnings, beating estimates with $1.59 EPS and $1.86 billion in revenue, and subsequently raised its quarterly dividend. Analysts maintain a "Moderate Buy" consensus for Agilent, with an average target price near $161.77.

**5. Thermo Fisher Scientific stock jumps as Evercore lifts target, with earnings in focus**
- Source: ts2.tech | 20260105T202149 | Somewhat-Bullish | Relevance: 69%
- Thermo Fisher Scientific Inc. shares rose about 2.4% after Evercore ISI raised its price target to $650 from $610, maintaining an "outperform" rating. The stock's performance places it in focus ahead of its late-January earnings report, where investors will seek insights into drugmaker and laboratory spending trends. The company's upcoming results will also provide updates on its China market exposure, its acquisition of Clario, and overall demand trends for lab tools and services.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 1, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2026-01-05 | Evercore ISI Gr | $160 | $155 | +3% |
| 2025-12-15 | Barclays | $165 | $165 | 0% |
| 2025-12-09 | Goldman Sachs | $170 | $0 | 0% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2026-01-05 | Evercore ISI Gr | up | Outperform |
| 2025-12-15 | Barclays | up | Overweight |
| 2025-12-09 | Goldman Sachs | init | Buy |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **MIXED** |
| Buys | 10 ($1.37M) |
| Sells | 18 ($1.60M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 44.9% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 7 / 3 |

**Top Holders:**
- Vanguard Group Inc: 12.0% (+0.1%)
- Blackrock Inc.: 9.2% (+1.0%)
- Massachusetts Financ: 4.4% (-6.0%)
- State Street Corpora: 4.4% (-0.1%)
- Wellington Managemen: 3.3% (+4.8%)

### Key Risks

1. Market regime shift could impact momentum names disproportionately.
2. Sector rotation risk if leadership changes from current market theme.
3. Earnings execution risk on next quarterly report.

### Catalysts

- Momentum building: MRS_10 improving +6.1% over 5 days suggests accumulation.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 2.12 elevated, pricing in significant growth expectations. Forward P/E 22.5x stretched relative to 10% growth. Quality metrics strong (ROE 21%, margin 19%). Institutional flow bullish (7 buying vs 3 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $41.8B |
| Beta | 1.29 |
| 52W Range | $96.43 - $160.27 |
| Short Interest | 1.3% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 2.12 |
| Forward P/E | 22.5 |
| Current P/E | 24.8 |
| YoY Growth | 10.3% |
| EPS Direction | STABLE |

### Technicals

MRS_10 strengthening from -0.6% to 5.5% (+6.1% in 5 days), confirming momentum buildup. Currently in upper STRENGTH zone (3.0-6.0%), cross-sectional ranking at 86th percentile. MRS_5 at 4.3% confirms short-term momentum alignment. Outperforming sector by 3.8pp, stock-specific strength. Full SMA alignment bullish (above 20/50/200 SMAs). MACD histogram positive (0.89), confirming momentum. OFD pattern: +FTN (Rally).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | 5.47% (CS: 86) | Strong |
| RSI_14 | 63.2 | Neutral |
| MACD Histogram | 0.89 | Bullish |
| vs SMA20 | 1.057x | Above |
| vs SMA50 | 1.021x | Above |
| vs SMA200 | 1.178x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** STRENGTH

### Trade Setup

- **Entry:** $147.60
- **Stop Loss:** $141.48 (4.1% risk)
- **Target:** $156.78 (R:R method)
- **Risk/Reward:** 1.50:1
- **Target Reasoning:** STRENGTH thesis targets 1.5x risk/reward based on historical edge

### Position Sizing

- **Shares:** 215
- **Position Value:** $31,734.00
- **Portfolio %:** 31.73%
- **Risk Dollars:** $1,320.00
- **Risk Per Trade:** 1.32%
- **Modifiers:** L1 110% | L2 120% | Combined 1.32x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | RISK_ON (MEDIUM) | 1.10x |
| L2 Sector | TREND (Zone A) | 1.20x |

*RISK_ON regime with strong participation and low volatility. VIX at 14.75 (6th percentile) with breadth at 63.5% signals healthy risk appetite. Fed dovish expectations and AI/semiconductor momentum are primary drivers, though elevated put/call ratio suggests smart money hedging. Focus on quality growth with awareness of potential complacency.*

### Earnings

**Next:** 2026-02-25 (Est: $1.37)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q4 | $1.58 | $1.59 | +0.4% |
| 2025Q3 | $1.37 | $1.37 | +0.2% |
| 2025Q2 | $1.26 | $1.31 | +3.6% |
| 2025Q1 | $1.27 | $1.31 | +3.0% |

---
*RULE-based L3 | 2026-01-07 08:25 | MRS_10*